-
Study aim
-
Determining the effectiveness of pentoxifylline in diabetic patients with covid-19 hospitalized in Shahid Rahmonun Hospital, Yazd.
-
Design
-
A controlled, parallel-group, double-blind, randomized, phase 2 clinical trial on 100 patients. The rand function of Excel software was used for randomization.
-
Settings and conduct
-
At least 24 inpatient diabetic patients with COVID-19 over the age of 18 and receiving either pentoxifylline (400 mg three times a day) or dexamethasone (4 mg every 12 hours) will be studied.
Improvement of patients is defined as arterial blood oxygen level of at least 93%, cessation of fever for 72 hours, and improvement of the general condition of patients. The levels of inflammatory markers, including serum interleukin 6, CRP, ESR, and ferritin, were checked in both groups at the beginning of the treatment and after one week from the start of the treatment. The person monitoring the patients will not be aware of the grouping done.
-
Participants/Inclusion and exclusion criteria
-
Patients:
Having type 1 or 2 diabetes
Infected with covid-19
Hospitalization in the non-specialized departments of Shahid Rahnamon Hospital, Yazd
Age above 18 years
-
Intervention groups
-
In the pentoxifylline group, patients are treated with this drug at the rate of 400 mg three times a day, and in the opposite group, patients are only treated with intravenous administration of dexamethasone 4 mg every 12 hours.
-
Main outcome variables
-
Levels of inflammatory markers including serum interleukin 6, CRP, ESR, and ferritin